Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Inventory (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Inventory for 5 consecutive years, with $25.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 37.42% to $25.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.8 million, a 37.42% increase, with the full-year FY2025 number at $25.8 million, up 37.42% from a year prior.
  • Inventory was $25.8 million for Q4 2025 at Rhythm Pharmaceuticals, up from $22.1 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $25.8 million in Q4 2025 to a low of $111000.0 in Q4 2021.
  • A 5-year average of $12.2 million and a median of $10.3 million in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: skyrocketed 2527.93% in 2022, then surged 37.42% in 2025.
  • Rhythm Pharmaceuticals' Inventory stood at $111000.0 in 2021, then surged by 2527.93% to $2.9 million in 2022, then skyrocketed by 195.65% to $8.6 million in 2023, then soared by 117.31% to $18.7 million in 2024, then skyrocketed by 37.42% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Inventory are $25.8 million (Q4 2025), $22.1 million (Q3 2025), and $18.9 million (Q2 2025).